Preparing for future pandemics
CEPI, the Coalition for Epidemic Preparedness Innovations, is a global partnership working to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats.
Find out more
Latest News
Latest News
The Caliciviruses, Reoviruses and Astroviruses
Attackers from these three viral families cause hundreds of millions of cases of severe diarrhoea and vomiting every year - many of them deadly.
Immune-boosting bacterial platform could aid nasal vaccines
Researchers at Abera Bioscience are set to test whether their bacterial-based platform could strengthen intranasal vaccines being developed to protect against epidemic and pandemic threats.
100 days to save eight million lives
Deploying effective COVID-19 vaccines in 100 days could have saved over eight million lives.
Canadian scientists to optimise vaccine process for faster outbreak response
Researchers will investigate whether they can speed up the creation of key vaccine ingredients to respond more quickly to future threats.
Promising human Rift Valley fever vaccine to enter Phase II clinical trials in Kenya
New CEPI-funded trial to launch in Kenya – the first ever Phase II trial of a Rift Valley fever vaccine in an endemic country mary text here
World-leading Coronavirus vaccine R&D roadmap to receive fresh updates
An important tool created to guide the development of vaccines against multiple potentially deadly Coronaviruses is being expanded.
New vaccine-making process could transform pandemic response
Scientists will receive CEPI funding to advance the RNAbox™, a process designed to scale production of mRNA vaccines at regional manufacturing sites.
Marburg – What it is, and what it is not
What is Marburg virus? How does it spread? Is there a cure? CEPI answers some of the most frequently asked online questions about this virus.
CEPI CEO Dr Richard Hatchett awarded Japanese Order of the Rising Sun
The award is one of the highest national accolades awarded to individuals who have made notable contributions to society.
Largest-ever Lassa fever study launches in-depth look at disease symptoms
Scientists in Nigeria are expanding their research into the deadly Lassa fever as part of the Enable research programme.
Latest News
We want to create a world in which epidemics and pandemics are no longer a threat to humanity.
CEPI is working to galvanise the development of new vaccines and other biologic countermeasures against diseases that could cause the next devastating epidemic or pandemic.
Our approach
Global Pandemic Preparedness Summit
The Global Pandemic Preparedness Summit 2024 aims to reinvigorate momentum for pandemic preparedness and response—helping to ensure that we can end future infectious disease outbreaks faster and more equitably.
Calls for Proposals
Innovators worldwide are invited to apply to our scientific programmes to advance the development and manufacture of vaccines and tools against epidemic and pandemic threats.
The Picornaviruses
Large, persistent and deadly outbreaks of a crippling infection caused by one member of this viral family meant that it was once among the most feared diseases in the world
The Viral Most Wanted
Join CEPI’s disease detectives as they investigate the viral families that have threatened human life for centuries.
$12.5 trillion
IMF’s estimate cost of the COVID-19 pandemic to the global economy through 2024
50+
Number of CEPI-supported vaccine candidates or platform technologies.
$2.8 billion
The minimum average cost to progress one vaccine each against 11 WHO priority infectious diseases
Emerging infectious diseases affect us all. They do not respect borders.
A commitment to equitable access informs every aspect of our work. It is core to CEPI’s vision of a world in which epidemics and pandemics are no longer a threat to humanity.
CEPI take a systems approach to equitable access, seeking to enable equitable access within a broad ecosystem of national and international public and private sector partners and networks.
We work towards this goal by enabling equitable access directly through financial investments and partnerships, and indirectly through advocacy and policy contributions to the evolving ecosystem.
